SK bioscience achieved strong topline growth in 2025, supported by the successful turnaround of its subsidiary IDT Biologika and robust sales across its proprietary vaccines and Sanofi-distributed product portfolio. Despite continued large-scale investment in clinical development, research and development (R&D), and manufacturing facilities, the company reduced its annual operating loss, laying the foundation for improved profitability.

According to the company’s preliminary consolidated results for 2025, fourth-quarter revenue reached KRW 184.2 billion, representing an approximately 17% increase year over year from KRW 156.8 billion. Full-year revenue totaled KRW 651.4 billion, more than doubling from KRW 267.5 billion in the previous year.

The company reported a full-year operating loss of KRW 123.5 billion, narrowing from KRW 138.4 billion in 2024, despite aggressive investment in R&D. This improvement reflects increased contributions from IDT and growth across key product portfolios, which helped offset cost pressures.

In particular, subsidiary IDT Biologika achieved a full-year turnaround just one year after its acquisition. IDT recorded FY2025 revenue of KRW 465.7 billion, up approximately 17% year over year, and delivered an operating profit of KRW 9.9 billion, compared with an operating loss in 2024. Strengthened partnerships with existing clients and productivity gains driven by process optimization contributed to the improved performance.

SK bioscience’s proprietary vaccines also demonstrated visible revenue growth in global markets. Influenza vaccine SkyCellflu maintained solid growth despite pricing pressure from the transition to trivalent formulations, supported by increased export volumes to Latin America and Southeast Asia.

Varicella vaccine SkyVaricella expanded its global export footprint while maintaining stable supply through the Pan American Health Organization (PAHO). In addition, shingles vaccine SkyZoster increased domestic market penetration through expanded local immunization programs, while advancing exports across Asian markets.

Sales growth was also notable for Sanofi-distributed products in South Korea, with related revenue increasing more than threefold year over year. RSV preventive monoclonal antibody Beyfortus, launched last year, contributed significantly during the autumn and winter RSV season. Pediatric combination vaccine Hexaxim and Tdap vaccine Adacel also supported revenue growth on the back of steady demand.

SK bioscience completed its move into the Songdo Global R&PD Center last month and has begun operating an integrated development system spanning research, process development, and commercial readiness. The company expects the Songdo hub to accelerate the advancement of its mid- to long-term pipeline and strengthen execution efficiency.

The 21-valent pneumococcal conjugate vaccine, co-developed with Sanofi, is currently in global Phase 3 clinical trials across major markets including the United States, Europe, and South Korea. In parallel, SK bioscience is advancing global regulatory and commercial manufacturing preparations following the expansion of its Andong L HOUSE production facility.

In addition, the company recently in-licensed RSM01, a preventive monoclonal antibody for RSV, from Gates MRI, a nonprofit medical research institute affiliated with the Gates Foundation. Backed by global exclusive supply rights, the program is positioned as a new growth driver targeting a global RSV prevention market estimated at approximately KRW 6 trillion.

Development of a next-generation Ebola vaccine, in collaboration with MSD, is also gaining momentum with support from CEPI (Coalition for Epidemic Preparedness Innovations). Furthermore, SK bioscience plans to advance its next-generation portfolio, including a pan-coronavirus vaccine, a next-generation pneumococcal vaccine, and an avian influenza vaccine, with clinical trial entry and IND submissions expected within the year.

SK bioscience plans to continue strengthening its global CDMO business centered on IDT while accelerating development of its core vaccine pipeline through the Songdo Global R&PD Center to secure sustainable mid- to long-term growth.